This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Glucagon
From Proteopedia
| Line 17: | Line 17: | ||
[[1bh0]] - hGLC (mutant)<br /> | [[1bh0]] - hGLC (mutant)<br /> | ||
[[1gcn]] - hGLC | [[1gcn]] - hGLC | ||
| - | + | == References == | |
| + | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 10:44, 6 March 2016
Contents |
Function
Glucagon (GLC) is a hormone which raises blood glucose level. GLC causes the liver to convert glycogen to glucose. GLC effect is opposite to that of insulin[1]. See some details in User:Mary Ball/Glucagon.
Relevance
Glucagon is injected in cases of severe glycemia[2]. Overdose of β blockers is treated with GLC. Epinephrin-resistant low blood pressure cases are treated with GLC. Pancreatic tumors may cause high levels of GLC.
3D Structures of glucagon
Updated on 06-March-2016
2g49 – hGLC preprotein residues 53-81+ insulin-degrading enzyme – human
1kx6, 2m5p, 2m5q – hGLC - NMR
1nau – hGLC (mutant) – NMR
1bh0 - hGLC (mutant)
1gcn - hGLC
References
- ↑ Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab. 2011 Oct;13 Suppl 1:118-25. doi:, 10.1111/j.1463-1326.2011.01454.x. PMID:21824265 doi:http://dx.doi.org/10.1111/j.1463-1326.2011.01454.x
- ↑ Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes. 2005 Apr;54(4):1100-7. PMID:15793249
